GenHealth.ai
Markets
Use Cases
Products
Company
Docs
Get a Demo
Automated Prior Authorization
with Generative AI. See how we support health plans and providers with prior auth.
Generative AI Healthcare Analytics
Use natural language to ask any question of your data: past, present, and future.
Search all medical codes
T40.725D
Adverse effect of synthetic cannabinoids, subsequent encounter
ICD10CM code
Similar Codes
ICD10CM codes
T40.725D
- Adverse effect of synthetic cannabinoids, subsequent encounter
T40.725A
- Adverse effect of synthetic cannabinoids, initial encounter
T40.725
- Adverse effect of synthetic cannabinoids
T40.725S
- Adverse effect of synthetic cannabinoids, sequela
T40.495D
- Adverse effect of other synthetic narcotics, subsequent encounter
T40.726D
- Underdosing of synthetic cannabinoids, subsequent encounter
T40.715D
- Adverse effect of cannabis, subsequent encounter
T40.7X5D
- Adverse effect of cannabis (derivatives), subsequent encounter
T40.4X5D
- Adverse effect of other synthetic narcotics, subsequent encounter
T40.721D
- Poisoning by synthetic cannabinoids, accidental (unintentional), subsequent encounter
HCPCS codes
D9630
- OTHER DRUGS AND/OR MEDICAMENTS
G6044
- Cocaine or metabolite
D9230
- ANALGESIA
G9561
- Patients prescribed opiates for longer than six weeks
D9248
- NON-INTRAVENOUS CONSCIOUS SEDATION
G9902
- Patient screened for tobacco use and identified as a tobacco user
G8947
- One or more neuropsychiatric symptoms
G9906
- Patient identified as a tobacco user received tobacco cessation intervention (counseling and/or phar
G9583
- Patients prescribed opiates for longer than six weeks
D9610
- THERAPEUTIC PARENTERAL DRUG
CPT4 codes
80352
- Cannabinoids, synthetic; 7 or more
80350
- Cannabinoids, synthetic; 1-3
80349
- Cannabinoids, natural
83992
- Phencyclidine (PCP)
80371
- Stimulants, synthetic
80359
- Methylenedioxyamphetamines (MDA, MDEA, MDMA)
82600
- Cyanide
83925
- Opiate(s), drug and metabolites, each procedure
80354
- Fentanyl
4306F
- Patient counseled regarding psychosocial and pharmacologic treatment options for opioid addiction (S